The vitamin D analogue EB 1089 prevents skeletal metastasis and prolongs survival time in nude mice transplanted with human breast cancer cells

Cancer Research

Volumn 60, Issue 16, 2000, Pages 4412-4418

  Abdaimi, Khadija El ^a   Dion, Natalie ^b   Papavasiliou, Vasilios ^a   Cardinal, Patrice Etienne ^b   Binderup, Lise ^c   Goltzman, David ^a   Ste Marie, Louis Georges ^b   Kremer, Richard ^a  

^a ROYAL VICTORIA HOSPITAL   (Canada)

^b UNIVERSITY OF MONTREAL   (Canada)

^c LEO PHARMA A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; CALCIUM; SEOCALCITOL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE ATROPHY; BONE METASTASIS; BREAST CANCER; CALCIUM BLOOD LEVEL; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FEMALE; MOUSE; NONHUMAN; OSMOTIC MINIPUMP; PARALYSIS; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE AND BONES; BONE NEOPLASMS; BREAST NEOPLASMS; CALCITRIOL; CALCIUM; CALCIUM CHANNEL AGONISTS; CELL DIVISION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HINDLIMB; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; TUMOR CELLS, CULTURED;

EID: 0034662629     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Bone metastases. The clinical problem
2. Osteolytic bone disease in breast cancer
3. Bone and cancer. Pathophysiology and treatment of metastases
4. A murine model of experimental metastasis to bone and bone marrow
5. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice
6. Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2
7. Effect of the bisphosphonate risedronate on bone metastases in a rat mammary adenocarcinoma model system
8. Effect of a newly developed bisphosphonate, YH529, on osteolytic bone metastases in nude mice
9. Vitamin D. New actions, new analogs, new therapeutic potential: Update 1995
10. Noncalcemic actions of 1, 25-dihydroxyvitamin D3 and clinical applications
11. 3 derivatives and breast tumor cell growth: Effect on intracellular calcium and apoptosis
12. 3 analogues: A novel class of potent inhibitors of proliferation and inducers of differentiation of human breast cancer cell lines
13. 3 inhibits the invasive potential of human breast cancer cells in vitro
14. 1α, 25-Dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells
15. Effects of 1, 25-dihydroxyvitamin D3 and its analogues on induction of apoptosis in breast cancer cells
16. 3 and their combination
17. Suppression of in vivo growth of human cancer solid tumor xenografts by 1, 25-dihydroxyvitamin D3
18. A vitamin D analogue (EB 1089) inhibits parathyroid hormone-related peptide production and prevents the development of malignancy-associated hypercalcemia in vivo
19. Inhibition of prostate cancer metastasis in vivo: A comparison of 1, 25-dihydroxyvitamin D (calcitriol) and EB 1089
20. 3 and EB 1089 on cell cycle kinetics and apoptosis in MCF-7 cells
21. Effects of synthetic vitamin D analogs on breast cancer cell proliferation in vivo and in vitro
22. Effects of a new synthetic vitamin D analogue, EB 1089, on the oestrogen responsive growth of human breast cancer cells
23. EB 1089: A novel vitamin D analogue, has strong antiproliferative and differentiation inducing effects on cancer cells
24. Metabolism of the vitamin D analog EB 1089: Identification of in vivo and in vitro liver metabolites and their biological activities
25. Pharmacokinetic studies of vitamin D analogues: Relationship to vitamin D binding protein (DBP)
26. EB 1089, a novel vitamin D analog with strong antiproliferative and differentiation-inducing effects on targets cells
27. EB 1089: A new vitamin D analogue that inhibits the growth of breast cancer cells in vivo and in vitro
28. Apoptotic regression of MCF-7 xenografts in nude mice treated with the vitamin D3 analog, EB 1089
29. Vitamin D3 analog, EB 1089, inhibits growth of subcutaneous xenografts of the human colon cancer cell line, LoVo, in a nude mouse model
30. Possible role of vitamin D in controlling breast cancer cell proliferation
31. Vitamin D receptors in breast cancer cells
32. 3 receptor in human breast cancer
33. Breast tumor cell lines from pleural effusions
34. Immunolocalization and quantification of noncollagenous bone matrix proteins in methylmethacrylate-embedded adult human bone in combination with histomorphometry
35. Embedding of bone samples in methymethacrylate: An improved method suitable for bone histomorphometry, histochemistry, and immunohistochemistry
36. E-Cadherin expression in human breast cancer cells suppresses the development of osteolytic bone metastases in an experimental metastatic model
37. Reduction in new metastases in breast cancer with adjuvant clodronate treatment
38. Clodronate decreases the frequency of skeletal metastases in women with breast cancer
39. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases
40. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer
41. Palliative pamidronate treatment in patients with bone metastases from breast cancer
42. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: Results from a multinational randomised controlled trial
43. Vitamin D analogs: New therapeutic agents for the treatment of squamous cancer and its associated hypercalcemia
44. Effects of a novel vitamin D analog MC903 on cell proliferation and differentiation in vitro and on calcium metabolism in vivo
45. 3 prolongs survival time of leukemic mice
46. 3, inhibits the growth of human breast cancer in vitro and in vivo without causing hypercalcemia
47. A phase I study of the vitamin D analogue EB 1089 in patients with advanced breast and colorectal cancer
48. Reversal of hypercalcemia with the vitamin D analogue EB1089 in a human model of squamous cancer
49. 3 on cell-cycle kinetics of T47D human breast cancer cells
50. 3, retinoic acid and dexamethasone
51. Regulation of myc oncogene expression in HL-60 leukemia cells by a vitamin D metabolite
52. 3 on proliferation and proto-oncogene expression in primary cultures of bovine parathyroid cells
53. Breast cancer prevention trial shows major benefit, some risk